Stay updated with breaking news from Robert Kim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chief Medical Officer Robert Kim has sold 24,552 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) on February 5, 2024, according to a recent SEC Filing.
51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable...
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...
The suit argues NJ's system of assigning students to schools based on residential addresses has exacerbated segregation by race, ethnicity and poverty
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular...